"Boston Children's in Boston, MA has always embodied a culture of innovation and scientific discovery, with the goal of improving the lives of children and families. This legacy continues today as we lead the world in pediatric research, empowering our clinicians and scientists to challenge the status quo and seek better answers for children everywhere."

During the past decade, Childrens Hospital Boston, Dana-Farber Cancer Institute. conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 6 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Childrens Hospital Boston, Dana-Farber Cancer Institute." #1 sponsor was "New Approaches to Neuroblastoma Therapy Consortium" with 8 trials, followed by "Children's Hospital of Philadelphia" with 2 trials sponsored, "Medical College of Wisconsin" with 2 trials sponsored, "Ann & Robert H Lurie Children's Hospital of Chicago" with 1 trials sponsored and "Bellicum Pharmaceuticals" with 1 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Childrens Hospital Boston, Dana-Farber Cancer Institute." #1 collaborator was "National Cancer Institute (NCI)" with 5 trials as a collaborator, "Dana-Farber Cancer Institute" with 4 trials as a collaborator, "Children's Healthcare of Atlanta" with 3 trials as a collaborator, "Children's Hospital Colorado" with 3 trials as a collaborator and "Lucile Packard Children's Hospital" with 3 trials as a collaborator. Other collaborators include 59 different institutions and companies that were collaborators in the rest 52 trials.

According to Clinical.Site data, the most researched conditions in "Childrens Hospital Boston, Dana-Farber Cancer Institute." are "Neuroblastoma" (10 trials), "Acute Lymphoblastic Leukemia" (2 trials), "Acute Myeloid Leukemia" (2 trials), "Diffuse Intrinsic Pontine Glioma" (2 trials) and "Neutropenia" (2 trials). Many other conditions were trialed in "Childrens Hospital Boston, Dana-Farber Cancer Institute." in a lesser frequency.

Most popular intervention types in "Childrens Hospital Boston, Dana-Farber Cancer Institute." are "Drug" (18 trials), "Biological" (6 trials), "Other" (2 trials), "Behavioral" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (3 trials), "Topotecan" (3 trials), "Azacitidine" (1 trials), "BPX-501 T cells" (1 trials) and "Balstilimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Childrens Hospital Boston, Dana-Farber Cancer Institute." are 26 trials for "All" genders.

Currently, there are NaN active trials in "Childrens Hospital Boston, Dana-Farber Cancer Institute.". undefined are not yet recruiting, 4 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Childrens Hospital Boston, Dana-Farber Cancer Institute., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Childrens Hospital Boston, Dana-Farber Cancer Institute., 15 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".